NEW YORK, Nov. 6, 2017 /PRNewswire/ -- At least 30% of the haematologistswe surveyed don't prescribe the 7 leading haemophilia B treatments we asked them about. But most are willing to consider them, so there's room for brands to grow. To seize that opportunity, you need to understand the market barriers that are preventing
Read the full report: https://www.reportlinker.com/p05175253
Market Access Impact: Haemophilia B (EU5) shows you how 7 barriers affect your market share, revealing which competitors you take share from, and which ones gets your lost share. Based on a survey of 150 haematologists, the report covers 6 major therapies from CSL Behring, Pfizer, Shire, and Swedish Orphan Biovitrum.
BeneFIX (nonacog alfa; Pfizer)
Feiba (Anti-Inhibitor Coagulant Complex; Shire)
Idelvion (albutrepenonacog alfa; CSL Behring)
MonoNine (Coagulation Factor IX [human]; CSL Behring)
Rixubis (nonacog gamma; Shire)
Exploring on Market Access issues
Market Access Impact: Haemophilia B (EU5) explores key issues affecting drug manufacturers. You'll learn: How barriers affect market access:
Which brands are physicians prescribing the most?
How are prescribing decisions being affected by market barriers?
Are some barriers having more impact than others?
How barriers affect your brand:
How many doctors prescribe your brand? How many don't, but would consider it?
Why don't doctors prescribe your brand? What do they choose instead?v
Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 150 medical haematologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world
All respondents have:
Been practising for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with haemophilia B in total in the last month
We conducted the survey between 1st and 12th May 2017. Read the full report: https://www.reportlinker.com/p05175253
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________ Contact Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/market-access-impact-haemophilia-b-eu5-300550503.html
Subscribe to our Free Newsletters!
LADA or Latent Autoimmune Diabetes of Adulthood is a form of type 1 autoimmune diabetes that can be ...
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...View All